PMCB (PharmaCyte Biotech) Debt-to-Equity : 0.00 (As of Jul. 2024)

View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Debt-to-Equity?

PharmaCyte Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $0.00 Mil. PharmaCyte Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $0.00 Mil. PharmaCyte Biotech's Total Stockholders Equity for the quarter that ended in Jul. 2024 was $53.04 Mil. PharmaCyte Biotech's debt to equity for the quarter that ended in Jul. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PharmaCyte Biotech's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of PharmaCyte Biotech was 0.02. The lowest was 0.01. And the median was 0.01.

PMCB's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

PharmaCyte Biotech Debt-to-Equity Historical Data

The historical data trend for PharmaCyte Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Debt-to-Equity Chart

PharmaCyte Biotech Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Debt-to-Equity

Get a 7-Day Free Trial

0.02

PharmaCyte Biotech Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PharmaCyte Biotech's Debt-to-Equity

For the Biotechnology subindustry, PharmaCyte Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Debt-to-Equity falls into.

PharmaCyte Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PharmaCyte Biotech's Debt to Equity Ratio for the fiscal year that ended in Apr. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	39.515
	=	0.00

PharmaCyte Biotech's Debt to Equity Ratio for the quarter that ended in Jul. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	53.041
	=	0.00

PharmaCyte Biotech (NAS:PMCB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PharmaCyte Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website

https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb	director	100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen	director	299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K	director
Carlos Trujillo	director, officer: CFO	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner	director, officer: Chairman, CEO, Pres and GC	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree	director, officer: Chief Science Officer	12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099